Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia

Novo Nordisk
The latest data on Novo's oral semaglutide will be "critical for commercial positioning," Evercore ISI analyst Umer Raffat wrote. (Novo Nordisk)

Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.

Wednesday, the company touted positive top-line data from a pair of studies—one pitting semaglutide against Novo’s own weekly GLP-1 injectable, Victoza, and one facing it off against Merck DPP-4 giant Januvia—that Evercore ISI analyst Umer Raffat called “critical for commercial positioning.”

Against Victoza, semaglutide put up “better than expected” results on its way to demonstrating noninferiority, as Bernstein’s Wimal Kapadia wrote in a note to clients. Those included reductions to HbA1c—a key measure of blood glucose control— of 1.3% and 1.2% at 26 and 52 weeks, respectively, versus Victoza’s 1.1% and 0.9%. And in the weight-loss department, semaglutide proved superior: Semaglutide patients lost 4.7 and 5.0 kg at the same 26- and 52-week markers, compared with Victoza’s 3.2 and 3.1 kg showings.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

“Novo now has an oral GLP-1 which is at least as good (if not better) than Victoza on A1C and weight loss ... but orals trump injectables—thereby making it a very compelling offering,” Raffat wrote in his own note. “From Novo’s perspective, this is likely as good an outcome as they could have hoped for,” he added.

In the Januvia head-to-head, Novo looked to simulate a real-world setting—complete with flexible dose adjustment—and semaglutide came through. In the semaglutide arm, 63% achieved target HbA1C levels of below 7% after 52 weeks of treatment, while just 28% of patients in the Januvia arm could say the same. And semaglutide put up significantly better weight-loss numbers, too, spurring a 2.9 kg reduction compared with Januvia’s 0.8 kg.

The superior showing hardly means Novo’s work is done, though.

“Commercially, it will be all about managing the dosing protocol (fasting time, quantity of water, spacing out meals/concomitant meds) just as well as Novo managed it in the trial,” Raffat wrote.

RELATED: Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?

While Novo inches closer to approval with oral semaglutide, its weekly injectable version of the drug, approved as Ozempic, is working its way through launch. The way Kapadia sees it, though, oral semaglutide performed so well against Victoza that it may just end up undermining its injectable counterpart.

“If oral sema gains more market share than we model (3.1% of US volumes in 2025), it will likely largely come at the expense of Ozempic (as well all other injectable GLP1s),” he wrote.

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.